Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Nature Boy who wrote (1830)	3/16/1999 1:19:00 PM
From: Jon Koplik	Respond to of 2135

I had the exact same thought. But, today appears to be one of those "throw the baby out with the bathwater" (I think that is the expression) kind of days ... Jon.

To: Nature Boy who wrote (1830)	3/16/1999 4:37:00 PM
From: Fred Puppet	Read Replies (2) \| Respond to of 2135

Nature Boy, according to the NYT article, Dr. Salvatore Pizzo of Duke University said "I have been skeptical for quite a while that angiostatin could be used as a drug candidate. Our yields were terrible". The experts at Bristol-Myers Squibb clearly agreed with Dr. Pizzo when they abandoned development. In contrast, you wrote "angiostatin and endostatin will be available, probably this year. And they'll work." Dr. Pizzo and the research team at B-M S have worked with angiostatin for years. When you flatly dismiss them and claim that all of them are wrong, you should provide some evidence. What research have you done with angiostatin?